ArticleEndocrine connections2026
Primary aldosteronism in South Asia: insights from a tertiary outpatient cohort in Bangladesh.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Primary aldosteronism (PA), the most common and potentially curable cause of secondary hypertension, remains under-investigated in the low- and middle-income countries (LMIC) of South Asia. Given the high population density in South Asia, including Bangladesh, the burden of PA is likely substantial. However, data on its prevalence are scarce. Objective: To determine the prevalence of PA among hypertensive patients attending an endocrine hypertension clinic at a tertiary hospital in Bangladesh. Methods: In this cross-sectional observational study, consecutive hypertensive patients with a plasma aldosterone-to-renin ratio (ARR) > 50 pmol/mIU underwent a seated saline suppression test (SST). PA was defined as a 4 h post-saline plasma aldosterone concentration (PAC) > 170 pmol/L. Participants with post-saline PAC ≤ 170 pmol/L were classified as non-PA. In the absence of adrenal vein sampling, subtyping was based on adrenal CT. Results: Of 365 screened patients (mean age 41.6 ± 12.8 years; 70.7% female), 218 (59.7%) had an ARR > 50 pmol/mIU. Of these, 207 completed the SST, with 114 (31.2% overall) meeting biochemical criteria for PA. Most participants with PA and non-PA were normokalemic, although hypokalemia was significantly more frequent in those with PA (27.7 vs 9.5%; P < 0.001). The majority of patients with PA had controlled office blood pressure on standard antihypertensive medications or stage 1 hypertension; 5.3% had resistant hypertension. Conclusion: PA appears highly prevalent among hypertensive patients in Bangladesh and often presents without classic features such as hypokalemia or resistant hypertension. These findings support recent guideline recommendations for broader PA screening in all individuals with hypertension to improve detection and cardiovascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.